Conference
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).
Authors
Bjarnason GA; Knox JJ; Kollmannsberger CK; Soulieres D; Ernst DS; Canil CM; Winquist E; Zalewski P; Hotte SJ; North SA
Volume
33
Pagination
pp. 4555-4555
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2015
DOI
10.1200/jco.2015.33.15_suppl.4555
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X